Skip to main content
Premium Trial:

Request an Annual Quote

Bioscience Investment Fund Gets Manager, $5M Commitment

Premium

RESEARCH TRIANGLE PARK, NC--The North Carolina Biotechnology Center here selected the Durham firm Eno River Capital to set up and manage the center's new Bioscience Investment Fund. The center also obtained a commitment from Charlotte-based NationsBank to invest up to $5 million in the fund, which will invest in new biotechnology and bioscience companies in the state.

The biotechnology center conceived of the fund last year to stimulate the creation and growth of new biotechnology and bioscience companies in North Carolina. The state's General Assembly appropriated $7.5 million for the fund in 1997, and the center is working to raise an additional $22.5 million from the state and from private investors.

Investments by the fund in North Carolina companies, expected to start being placed by early fall, will range from $500,000 to $2 million per company, according to Tom Laundon, vice-president of business and technology development at the center.

Filed under

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.